Abstract Treatment-resistant depression (TRD) is a subset of Major Depressive Disorder
which does not respond to traditional and first-line therapeutic options. There are several …

Objective To compare the efficacy and discontinuation of augmentation agents in adult
patients with treatment-resistant depression (TRD). We conducted a systematic review and …

Treatment‐resistant depression (TRD) is common and associated with multiple serious
public health implications. A consensus definition of TRD with demonstrated predictive utility …

Numerous placebo-controlled studies have demonstrated the ability of ketamine, an NMDA
receptor antagonist, to induce rapid (within hours), transient antidepressant effects when …

Objectives: To provide guidance for the management of mood disorders, based on scientific
evidence supplemented by expert clinical consensus and formulate recommendations to …

BackgroundC-reactive protein (CRP) is a candidate biomarker for major depressive disorder
(MDD), but it is unclear how peripheral CRP levels relate to the heterogeneous clinical …

Importance The placebo effect in depression clinical trials is a substantial factor associated
with failure to establish efficacy of novel and repurposed treatments. However, the …

Objectives. This 2013 update of the practice guidelines for the biological treatment of
unipolar depressive disorders was developed by an international Task Force of the World …

Context Atypical antipsychotic medications are commonly used for off-label conditions such
as agitation in dementia, anxiety, and obsessive-compulsive disorder. Objective To perform …

Kynurenine pathway (KP) metabolites are believed to be a link between inflammation and
depression through effects on brain glutamate receptors. However, neither the relationship …